Arix Bioscience Plc (ARIX)-Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company's businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company's key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.
The profile contains critical company information including:
- Business description-A detailed description of the company's operations and business divisions.
- Corporate strategy-Analyst's summarization of the company's business strategy.
- SWOT Analysis-A detailed analysis of the company's strengths, weakness, opportunities and threats.
- Company history-Progression of key events associated with the company.
- Major products and services-A list of major products, services and brands of the company.
- Key competitors-A list of key competitors to the company.
- Key employees-A list of the key executives of the company.
- Executive biographies-A brief summary of the executives' employment history.
- Key operational heads-A list of personnel heading key departments/functions.
- Important locations and subsidiaries-A list and contact details of key locations and subsidiaries of the company.
- Detailed financial ratios for the past five years-The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods-The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.
Arix Bioscience Plc (Arix Bioscience), formerly Perceptive Bioscience Investments Ltd invests exclusively in diverse healthcare and life science companies. The company sources, and finances the companies for accelerating the commercialization of their novel medical innovations. Its investment portfolio encompasses companies that develop therapies to address the unmet medical need of oncology, infectious diseases, orphan diseases, and gene therapies. It works in collaboration with universities, research institutions, and biopharmaceutical companies for advancing new technologies. The company serves both public and private sector companies. It has subsidiaries in Australia, Scotland, the US, and the UK. Arix Bioscience is headquartered in London, the UK.
Arix Bioscience Plc Key Recent Developments
Nov 15,2018: Arix Bioscience plc: Pharmaxis Releases Positive Results of Phase 1 Clinical Trial for Second LOXL2 Inhibitor Compound
Oct 11,2018: Arix Bioscience plc : Pharmaxis Releases Positive Results of Phase 1 Clinical Trial for LOXL2 Inhibitor Compound
Sep 26,2018: Fred Hutch launches business partnership: LAB591
Sep 12,2018: ARIX Bioscience announces Board Changes, appointment of Arthur Pappas to the Board of Directors, David U'Prichard to retire from Board
Sep 04,2018: Arix Bioscience: Changes announced to executive team to accelerate growth and strategy
Key benefits of buying this profile include:
You get detailed information about the company and its operations to identify potential customers and suppliers.
- The profile analyzes the company's business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.
Understand and respond to your competitors' business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
- The company's core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.
Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.
Scout for potential investments and acquisition targets, with detailed insight into the companies' strategic, financial and operational performance.
- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.
Gain key insights into the company for academic or business research.
- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.
Note: Some sections may be missing if data is unavailable for the company
Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Section 1-About the Company 6
Arix Bioscience Plc-Key Facts 6
Arix Bioscience Plc-Key Employees 7
Arix Bioscience Plc-Key Employee Biographies 8
Arix Bioscience Plc-Key Operational Employees 9
Arix Bioscience Plc-Major Products and Services 10
Arix Bioscience Plc-History 11
Arix Bioscience Plc-Company Statement 12
Arix Bioscience Plc-Locations And Subsidiaries 13
Head Office 13
Other Locations & Subsidiaries 13
Section 2-Company Analysis 15
Company Overview 15
Arix Bioscience Plc-Business Description 16
Arix Bioscience Plc-Corporate Strategy 17
Arix Bioscience Plc-SWOT Analysis 18
SWOT Analysis-Overview 18
Arix Bioscience Plc-Strengths 18
Arix Bioscience Plc-Weaknesses 19
Arix Bioscience Plc-Opportunities 20
Arix Bioscience Plc-Threats 21
Arix Bioscience Plc-Key Competitors 22
Section 3-Company Financial Ratios 23
Financial Ratios-Capital Market Ratios 23
Financial Ratios-Annual Ratios 24
Performance Chart 26
Financial Performance 26
Financial Ratios-Interim Ratios 27
Financial Ratios-Ratio Charts 28
Arix Bioscience Plc, Recent Deals Summary 29
Section 4-Company's Recent Developments 31
Nov 15, 2018: Arix Bioscience plc: Pharmaxis Releases Positive Results of Phase 1 Clinical Trial for Second LOXL2 Inhibitor Compound 31
Nov 15, 2018: Arix Bioscience plc: Pharmaxis Releases Positive Results of Phase 1 Clinical Trial for Second LOXL2 Inhibitor Compound 36
Oct 11, 2018: Arix Bioscience plc : Pharmaxis Releases Positive Results of Phase 1 Clinical Trial for LOXL2 Inhibitor Compound 41
Oct 11, 2018: Arix Bioscience plc : Pharmaxis Releases Positive Results of Phase 1 Clinical Trial for LOXL2 Inhibitor Compound 45
Sep 26, 2018: Fred Hutch launches business partnership: LAB591 49
Sep 12, 2018: ARIX Bioscience announces Board Changes, appointment of Arthur Pappas to the Board of Directors, David U'Prichard to retire from Board 50
Sep 04, 2018: Arix Bioscience: Changes announced to executive team to accelerate growth and strategy 51
May 31, 2018: Arix Bioscience Forms Strategic Collaboration with Evotec AG and Fred Hutchinson Cancer Research Center to Foster New Companies in Cancer and Infectious Diseases 52
May 31, 2018: Evotec forms academic BRIDGE 'LAB591' with Arix Bioscience and Fred Hutchinson Cancer Research Center 53
May 08, 2018: Arix Bioscience plc: Autolus Files for Proposed Initial Public Offering in the United States 54
Section 5-Appendix 55
Ratio Definitions 55
About GlobalData 59
Contact Us 59
List of Figures
Arix Bioscience Plc, Performance Chart (2016-2017) 26
Arix Bioscience Plc, Ratio Charts 28
List of Tables
Arix Bioscience Plc, Key Facts 6
Arix Bioscience Plc, Key Employees 7
Arix Bioscience Plc, Key Employee Biographies 8
Arix Bioscience Plc, Key Operational Employees 9
Arix Bioscience Plc, Major Products and Services 10
Arix Bioscience Plc, History 11
Arix Bioscience Plc, Other Locations 13
Arix Bioscience Plc, Subsidiaries 13
Arix Bioscience Plc, Key Competitors 22
Arix Bioscience Plc, Ratios based on current share price 23
Arix Bioscience Plc, Annual Ratios 24
Arix Bioscience Plc, Annual Ratios (Cont...1) 25
Arix Bioscience Plc, Interim Ratios 27
Arix Bioscience Plc, Recent Deals Summary 29
Currency Codes 55
Capital Market Ratios 55
Equity Ratios 56
Profitability Ratios 56
Cost Ratios 57
Liquidity Ratios 57
Leverage Ratios 58
Efficiency Ratios 58
Single User License:
Corporate User License:
Albion Venture Capital Trust plc
Woodford Patient Capital Trust plc
Insight Venture Partners, LLC
Kings Arms Yard VCT PLC
Crown Place VCT Plc
Advent Life Sciences LLP
Arix Bioscience Plc, SWOT analysis, SWOT, Strengths, Weaknesses, Opportunities, Threats, Corporate Strategy, Key Ratios, Share Data, Performance, Financial Performance, Overview, Business Description, Major Product, Brands, History,Key Employees, Key Operational Heads, Strategy, Key Competitors, Company Statement, Capital Market Ratios, Financial Ratios, Annual Ratios, Interim Ratios, Ratio Charts
select a license
NEWSLETTER BY CATEGORY
The report was very informative and gives me an interesting view on the Indian market.... "Area Sales Manager, Muhlen Sohn GmbH & Co. KG"
We would like to thank the entire team of Ken Research in showcasing professionalism in research and quick turnaround time. We have had multiple research reports from Ken Research. The deadline communicated for research was duly met. The research reports were covering many aspects in detail. This showcases their endeavor and care for client satisfaction and a strong understanding of the clients’ requirements. Thank you again for your help... "Group Vice President Strategy, Aliaxis"
I appreciate their diligence and determination in customizing the research project. The data proves to be valuable and accurate. I would, in future, definitely use their services again... "Technical Marketing Manager, Ascendis Health Limited"
I would like to thank Ken research team for meeting our report deliverables. The report is very good and we appreciate your well cooperation. ... "., Coldwell Banker - Riyadh "
The research you conducted was very helpful for us and the integrity of your research approach gave us great confidence in the data. Look forward to collaborating again in future... "International and Business Dev. Director, Duta Abadi Primantara"